Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

Viking Therapeutics (VKTX) presents a compelling asymmetric opportunity, with its oral GLP-1 drug VK2735 showing unprecedented tolerability that could significantly expand the obesity market. Despite the stock trading near 52-week lows amid broader biotech sector headwinds, sophisticated institutional investors have accumulated over $150 million in bullish positions, with Goldman Sachs notably eliminating all downside hedges, signaling strong conviction ahead of critical Phase 2 oral data expected in Q4 2025. This institutional activity, combined with a 30% short interest and manufacturing readiness, suggests a substantial revaluation potential, diverging from the market's current low implied probability of success.

Analysis

Viking Therapeutics (VKTX) presents a significant valuation disconnect, with its stock trading near 52-week lows primarily due to broad biotech sector headwinds rather than company-specific issues. The core of the investment thesis rests on its dual GLP-1/GIP agonist, VK2735, which demonstrated a key competitive advantage in its injectable form: unprecedented tolerability, with a 13% discontinuation rate that was statistically indistinguishable from placebo. This profile starkly contrasts with market leaders from Novo Nordisk and Eli Lilly, potentially enabling VKTX to expand the total addressable market for obesity treatments, which is projected to reach $200 billion by 2030. A pivotal catalyst is the upcoming Phase 2 oral data for VK2735, expected in Q4 2025, which represents a major binary event. Sophisticated institutional investors appear to be positioning for a positive outcome, having amassed over $150 million in bullish positions, highlighted by Goldman Sachs eliminating 100% of its put options while increasing calls by 350%. This institutional conviction is juxtaposed against an extremely high short interest of 30% of the float, creating a scenario ripe for a potential short squeeze. The company has also proactively de-risked its manufacturing supply chain through a partnership with CordenPharma. The market is currently implying a mere 3.5% probability of success for VK2735, a significant discount to the 45-50% historical average for metabolic drugs with positive Phase 2 data, suggesting a pronounced asymmetric risk-reward opportunity.

Key Decisions for Investors

• Investors should closely monitor Viking Therapeutics ahead of the pivotal Phase 2 oral data release for VK2735 expected in Q4 2025, which is a key binary catalyst that could fundamentally re-rate the stock.
• Evaluate the highly asymmetric risk-reward profile, where the current valuation implies a low probability of success despite a differentiated drug tolerability profile and significant de-risking of its manufacturing.
• Note the extreme divergence between institutional positioning, with funds accumulating over $150 million in bullish bets, and the high 30% short interest, which sets up potential for significant volatility and a possible short squeeze on positive news.
• Consider that the stock's depressed price is attributed to sector-wide weakness, not a flawed asset, creating a potential opportunity to invest in a drug with a superior clinical profile at a distressed valuation before the market's focus returns to biotech fundamentals.